Pluri Inc. Research and Development in Process
Pluri Inc. (PLUR) reported Research and Development in Process of $228.00 thousand for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-09-21
- Pluri Inc. research and development in process for fiscal 2022 was $228.00K, a 51.18% decline from fiscal 2021.
- Pluri Inc. research and development in process for fiscal 2021 was $467.00K, a 69.26% decline from fiscal 2020.
- Pluri Inc. research and development in process for fiscal 2020 was $1.52M.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2022-06-30 | $228.00K 10-K · filed 2022-09-21 |
| 2021-06-30 | $467.00K 10-K · filed 2022-09-21 |
| 2020-06-30 | $1.52M 10-K · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |